Figure 1.

The flow chart of patient selection, PD-L1 expression, and bioinformatics analysis. (A) The flow charts and treatment flow chart. We selected 24 cases in this retrospective analysis. The treatment strategy included mono anti-PD-1 therapy (n = 3), anti-PD-1 + apatinib combined therapy (n = 20), and anti-PD-1 + radiotherapy (n = 1). The PD-L1 detective flow chart: among 24 patients, only 13 patients received PD-L1 expression testing. The positive ratio was 23% (3/13). The gene mutation flow chart: the large mutation landscape was composed of the panel detection data of 20 cases and whole exome sequencing (WES) data of 8 cases. We also used bioinformatics analyses, such as some biomarkers, using WES data. The transcriptome analysis flow chart: we had accompanied studies using transcriptome data of 7 cases, including key signal pathways and the immune microenvironment. (B) Specific information of patients in biomarker exploring. Before treatment, there were 8 patients with whole exon sequencing, 7 patients with RNA sequencing, and 8 patients with panel sequencing data.